NDA 206628 · Hq Spclt Pharma
Dexmedetomidine Hydrochloride
Dexmedetomidine Hydrochloride · Intravenous
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 21, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,922
279 Phase 3, 159 recruiting
FAERS reports
5,243
5,001 serious, 568 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 2, 2026.
Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is a alpha 2 adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection by continuous infusion not to exceed 24 hours. (1.1) • Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. (1.2) 1.1 Intensive Care Unit Sedation Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection should be administered by continuous infusion not to exceed 24 hours. 1.2 Procedural Sedation Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.
Mechanism: Dexmedetomidine is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity was observed in animals following slow intravenous infusion of low and medium doses (10 mcg/kg to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (greater than or equal to 1000 mcg/kg) or with rapid intravenous administration.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 19, 2016 Supplement 2 · Efficacy LetterLabel
- Oct 21, 2015 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
4 products under this application
- DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexmedetomidine" as an intervention, any sponsor and status, largest first.
- Perioperative Dexmedetomidine and Long-term Survival After Cancer SurgeryPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT06030804 · 4,532 participants (planned) · Start Sep 12, 2023 · Primary completion Sep 2027
Drug: Dexmedetomidine; Placebo · For: Elderly; Cancer Surgery; Dexmedetomidine and 1 more
Sites: Hefei, China; Beijing, China; Chongqing, China · 40 sites in all
- Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary InterventionsPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07847580 · 2,500 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2029
Drug: Intranasal dexmedetomidine; Normal Saline · For: Coronary Heart Disease; Coronary Artery Disease
Sites: Hangzhou, China
- Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery PatientsPivotal-lookingRecruiting
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04289142 · 2,400 participants (planned) · Start Dec 1, 2019 · Primary completion Jul 2028
Drug: Dexmedetomidine Hydrochloride Group · For: Delirium; Cognitive Dysfunction; Cognition Disorder and 14 more
Sites: Vancouver, Canada; London, Canada; Toronto, Canada · 8 sites in all
- Perioperative Multimodal Analgesia Protocol for Supratentorial CraniotomyPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06406829 · 2,000 participants (planned) · Start Feb 9, 2026 · Primary completion Dec 31, 2026
Drug: Dexmedetomidine; Normal saline · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
- Perioperative Multimodal Analgesia for Supratentorial CraniotomyPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07441421 · 2,000 participants (planned) · Start Mar 9, 2026 · Primary completion Dec 31, 2027
Drug: Dexmedetomidine · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
Sites: Beijing, China
- Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576517 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2029
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 3 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576543 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2030
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 4 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Comparison of Epidural Labor Analgesia With Dexmedetomidine or SufentanilPivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT03622047 · 1,800 participants (planned) · Start Aug 15, 2018 · Primary completion Aug 1, 2020
Drug: Dexmedetomidine ropivacaine; No analgesia labor · For: Pharmacological Action
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use608
- drug ineffective450
- bradycardia418
- hypotension313
- cardiac arrest263
- drug interaction261
- agitation202
- product use in unapproved indication174
- respiratory failure167
- delirium153
- pyrexia146
- tachycardia146
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 8 |
| 2009 | 18 |
| 2010 | 24 |
| 2011 | 29 |
| 2012 | 30 |
| 2013 | 90 |
| 2014 | 103 |
| 2015 | 80 |
| 2016 | 220 |
| 2017 | 244 |
| 2018 | 211 |
| 2019 | 348 |
| 2020 | 512 |
| 2021 | 571 |
| 2022 | 552 |
| 2023 | 613 |
| 2024 | 659 |
| 2025 | 582 |
| 2026 | 342 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 2, 2026
Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24). Marketed by WG Critical Care
Current · updated Nov 2, 2026
Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04). Marketed by WG Critical Care
Current · updated Nov 2, 2026
Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24). Marketed by WG Critical Care
Current · updated Nov 2, 2026
Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04). Marketed by WG Critical Care
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials.
Lewis K, Alshamsi F, Carayannopoulos KL, et al. · Intensive Care Med 2022 · Meta-Analysis, Systematic Review
- Dexmedetomidine for adult cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.
Poon WH, Ling RR, Yang IX, et al. · Anaesthesia 2023 · Systematic Review, Meta-Analysis
- Outcomes of dexmedetomidine versus propofol sedation in critically ill adults requiring mechanical ventilation: a systematic review and meta-analysis of randomised controlled trials.
Heybati K, Zhou F, Ali S, et al. · Br J Anaesth 2022 · Meta-Analysis, Systematic Review
- Efficacy of perioperative dexmedetomidine in postoperative pain and neurocognitive functions in orthopedic surgery: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Zhang X, Leng Y, Yuan X, et al. · Int J Surg 2025 · Meta-Analysis, Systematic Review
- Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: a systematic review and network meta-analysis.
Burry LD, Cheng W, Williamson DR, et al. · Intensive Care Med 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Dexmedetomidine for analgesia and sedation in newborn infants receiving mechanical ventilation.
Lim JY, Ker CJ, Lai NM, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Hq Spclt Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.